• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Mylan shareholders vote against executive pay package, but re-elect board

June 22, 2017 By Sarah Faulkner

MylanAt the company’s annual meeting, Mylan (NSDQ:MYL) shareholders re-elected the drugmaker’s board despite a campaign spearheaded by major investors to do otherwise.

The campaign hoped to encourage shareholders to vote down most of the board’s directors in response to Mylan’s drug pricing practices for its EpiPen device. The influential proxy advisory firm, ISS, also urged shareholders last week to vote against the directors.

Although Mylan’s board was re-elected, the campaign managed to land a win, since shareholders voted against the company’s executive compensation structure. Earlier this year, Mylan revealed that chairman Robert Coury reeled in a $97 million pay package in 2016.

Unseating a director would have required at least 2/3 of votes cast, as well as more than half of Mylan’s outstanding shares.

The company’s annual meeting was held in Amsterdam. Quirijn Bongaerts, a shareholder from the Dutch small shareholders association VEB, reportedly challenged Coury regarding his executive compensation and ethics.

Mylan has previously defended Coury’s pay, writing that “the Board focused on structuring his compensation in this new role to ensure long-term retention for at least a 5-year period and to ensure that his compensation was significantly weighted toward equity-based compensation to further align his interests with those of our shareholders.”

Also today, a report from STAT found that Mylan offered discounts to at least 6 state Medicaid programs in exchange for “preferred” status that would make it easier for patients to get its EpiPen device. Competitor devices, like Sanofi‘s (NYSE:SNY)Auvi-Q, would require special requests to be covered.

This kind of arrangement is legal and common in the pharmaceutical industry, but experts pointed out that this new information could bolster Sanofi’s antitrust case against the EpiPen-maker.

Material from Reuters was used in this report.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news

Filed Under: Auto-injectors, Drug-Device Combinations, Featured, Pharmaceuticals, Policy, Wall Street Beat Tagged With: Mylan, Sanofi-Aventis

IN CASE YOU MISSED IT

  • Abbott will spend $450M to up FreeStyle Libre production in Ireland
  • Better Therapeutics Q2 beats Street as it prepares to submit diabetes therapy for FDA review
  • Study backs Fluidx embolic device for vessel filling
  • Senseonics stock is up as it sticks by revenue guidance
  • Rapid Dose closes first tranche of $5M financing

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS